<DOC>
	<DOCNO>NCT01101776</DOCNO>
	<brief_summary>This observational multicentric study plan assess tolerability Rebif New Formulation Australian clinical set incidence injection site reaction ( ISRs ) . The study allow comparison tolerability data historical data Rebif New classic formulation , use pre- specify preferred term treatment emergent adverse event do historical study . In addition , study analyse whether interaction ( ) nurse impact tolerability impact Rebif New Formulation patient 's Quality Life .</brief_summary>
	<brief_title>Post Marketing Surveillance Study Evaluate Tolerability Rebif® New Formulation Patients With Relapsing Multiple Sclerosis Australian Clinical Setting .</brief_title>
	<detailed_description>The disease-modifying therapy multiple sclerosis ( MS ) aim slow disease process consequent damage central nervous system . This study open-label , multicentric study plan assess tolerability Rebif New Formulation Australian clinical set incidence ISRs . A total 100 subject relapse MS across approximately 20 site Australia enrol study . Subject visit schedule baseline ( month 0 ) month 3 , 6 , 9 12 data related demographic factor , disease history , quality life adverse drug reaction ( ADRs ) record case report form ( CRF ) . OBJECTIVES Primary Objective : - To assess tolerability Rebif New Formulation Australian clinical set incidence ISRs Secondary Objectives : - Observe number reason miss injection Rebif New Formulation 3 , 6 , 9 12 month - Assess change quality life [ Multiple Sclerosis International Quality Life Questionaire ( MusiQoL ) ] 6 12 month compare baseline - Number type ( telephone , face-to-face , write ) interaction nurse support 3 , 6 , 9 12 month . - Assess relapse rate 12 month - Assess difference tolerability Rebif New Formulation subject treatment naïve previous MS therapy - Observe proportion subject dose reduction 22 mcg result tolerability</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-beta</mesh_term>
	<mesh_term>Interferon beta-1a</mesh_term>
	<criteria>Ambulatory patient Multiple Sclerosis : 1. experience two relapse within last 2 year . 2. tolerate current MS therapy . Patients 18 year age . Patients Expanded Disability Status Scale ( EDSS ) score &lt; 6.0 . Patients give informed consent participate study . Subjects diagnosis form MS relapse MS. Contraindicated medical condition IFN beta1a define Product Information i.e : woman plan become pregnant whilst therapy ; subject severe depressive disorder and/or suicidal ideation ; epileptic subject seizures adequately control treatment Subjects know hypersensitivity natural recombinant interferon beta , mannitol , poloxamer , methionine , sodium acetate buffer benzyl alcohol . Subjects pregnant and/or breastfeed . Subjects currently Rebif New Formulation . Subjects currently experience relapse .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Multiple Sclerosis , relapse</keyword>
	<keyword>Rebif New Formulation</keyword>
	<keyword>Interferon beta-1a</keyword>
</DOC>